HIV Cases Rising Among 50+ Age Group, Says Alarming Lancet Report
Last Updated:
The report warns that HIV spreads via shared needles, unsafe injections and improper transfusions, posing a risk not just to youth but to people of all ages
A recent report published in The Lancet has raised alarms among health experts, highlighting a sharp rise in HIV cases among people aged 50 and above.
While HIV is commonly linked to sexual transmission and often perceived as a disease affecting younger individuals, the report stresses that the virus can spread through multiple routes, including shared needles, unsafe injections, and improper blood transfusions, making it a risk for people of all ages.
The study, published in The Lancet Healthy Longevity journal, reveals that HIV prevalence among older adults now surpasses that of younger individuals. Dr. Louiser Olubayo of the Sydney Brenner Institute for Molecular Bioscience notes that most awareness campaigns focus primarily on youth, leaving the older population overlooked. This age group often assumes they're not at risk, a misconception deeply rooted in societal attitudes.
Preventing HIV among the elderly requires a proactive approach. First, it's vital to recognise that HIV is entirely treatable, and early diagnosis greatly improves outcomes. However, older individuals are less likely to get tested, often resulting in delayed detection and limited access to timely treatment.
Experts recommend annual HIV testing, which is both affordable and widely available, typically costing less than Rs 100.
Raising awareness among the elderly is crucial, and government-led campaigns are needed to promote regular HIV testing in this age group. Encouraging safe sex practices and ensuring hygienic injection methods are also key to prevention. Seniors should seek immediate medical attention if they experience symptoms like excessive sweating, tongue blisters, persistent fever, fatigue, weakness, sudden weight loss, or unexplained skin rashes.
First Published:
May 08, 2025, 17:41 IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
This drug offers 99.9% protection against HIV, but there's a catch
The US FDA has approved lenacapavir, the first twice-yearly injection for HIV prevention, which provides near-complete protection. However, its cost — ₹24 lakh per shot — may make it inaccessible in India
New Indian Express
3 hours ago
- New Indian Express
Sambalpur begins Rs 55 crore water pipeline upgrade
SAMBALPUR: After years of recurring waterborne disease outbreaks and mounting public pressure, the Sambalpur Municipal Corporation (SMC) is set to begin major infrastructure upgrade to replace 55 kilometres of outdated and damaged drinking water supply pipelines across the city. This massive project, awarded to Bhubaneswar-based Shivjyoti Conpro Pvt Ltd, will be completed within 18 months at an estimated cost of Rs 55 crore. The most critically damaged pipelines will be replaced in the first phase within six months. This step comes after five jaundice outbreaks since 2014, with the most recent occurring after Sital Sasthi last year, affecting over 150 people. The outbreaks were linked to contaminated water supply caused by pipelines running through open drains, allowing sewage to seep into drinking water lines. In 2014, the then chief minister Naveen Patnaik had announced a complete overhaul of the system, but only partial work was carried out in selected areas, leaving the system vulnerable for nearly a decade. General manager, WATCO, Brahmeshwar Das said, 'The project will be executed at an estimated cost of Rs 55 crore. In the initial phase, pipelines in the worst condition will be replaced within six months. The overall target is to complete the entire 55-kilometre stretch within 18 months.' WATCO officials said the project will also expand water supply to under-served areas like Balaji colony and Marutivihar with 18,000 new household connections planned, while 8,000 is to be done in first phase. Additionally, two new treatment plants with a combined capacity of 100 MLD are proposed at Ainthapali (65 MLD) and near Sambalpur University (35 MLD). City health officials say diarrhoea, jaundice, and hepatitis remain endemic in parts of Sambalpur during monsoon. The project is expected to significantly reduce the city's vulnerability to waterborne diseases and improve health outcomes for thousands of residents.
Hans India
6 hours ago
- Hans India
ICMR's affordable test kits boost diagnosis of genetic blood disorders in India
New Delhi: Simple and affordable point-of-care (POC) test kits, developed by scientists at the Indian Council of Medical Research (ICMR), are enhancing the diagnosis of genetic blood disorders like Haemophilia A, von Willebrand disease (VWD) and sickle cell disease (SCD) in the country. Haemophilia A, VWD, and SCD are serious inherited bleeding disorders, which often go undiagnosed because the testing is expensive and only available at a few specialised hospitals. India bears a significant burden from Haemophilia A. Estimates suggest around 136,000 individuals are affected, but only a small fraction are diagnosed and registered. While the prevalence of VWD in India is estimated at 1 per 12,000 in some regions, limited studies suggest a 10 per cent prevalence among inherited bleeding disorders. In the case of SCD, the disease is particularly prevalent in India, especially among the tribal population (57 per cent), though it also affects non-tribals (43 per cent). 'We have now multiple tests that are made in India and can diagnose blood disorders. That is something we all should be proud of,' Dr Manisha Madkaikar, Director, ICMR-Centre for Research, Management, and Control of Haemoglobinopathies (CRMCH) in Chandrapur district of Maharashtra, told IANS. ICMR-National Institute of Immunohaematology (NIIH) developed a POC test kit for diagnosing Haemophilia A, VWD, which can also be used at primary health centres (PHCs), bringing diagnosis closer to the people who need it most. Notably, 'the POC test costs just Rs 582 per patient, while the current lab-based tests cost around Rs. 2,086. Using this kit could help detect over 83,000 undiagnosed cases,' Madkaikar said, adding that the kits can 'save the health system about Rs 42 crore -- three times cheaper than the current method'. These tests are being integrated into the national health programme at the PHC level in different states. 'Using the cost-effective POC kits at PHCs and other local health centres can help India find and treat bleeding disorders early, improve patient outcomes, and cut healthcare costs dramatically,' the senior scientist said. In addition, 'the World Federation for Hemophilia has also shown interest in procuring these tests for deployment in countries where the disease is prevalent,' Madkaikar said. Further, to support the fight against SCD, ICMR-NIIH in Mumbai and CRMCH in Chhattisgarh have been officially chosen by the government to test and approve new diagnostic kits. "So far, they have checked and approved 30 different kits, including simple tests that can be done on the spot (like finger-prick tests); lab-based tests like HPLC; and tests that detect the disease at the genetic level," said Madkaikar, adding that these test kits may play a key role in the national screening programme for SCD that targets a population of 7 crore in the country. While the initial manufacturer's quote for the diagnostic test was Rs 350 per test, a comprehensive analysis by ICMR determined that POC tests for sickle cell disease/trait among the high-risk population in India would be cost-effective if procured at Rs 100 per test or below. Subsequently, the new kits validated by ICMR-NIIH are priced below Rs 50 per test. 'When the national sickle cell elimination mission was to be launched, we had only two point of care tests, which were recommended under the nation, and both of them were paid outside, and the cost of that was nearly 350 rupees," Madkaikar said. "But now multiple indigenous companies have come up with their point of care test. We now have different tests, right from solubility to point-of-care to molecular -- all made in India and easily available," the scientist said.
